Home » Newsletters » BioWorld Science

BioWorld Science

April 8, 2020

View Archived Issues

Minimal phenotyping gives minimal insights into MDD genetics

Stopping tau in its tracks

Phase IIa study of golexanolone shows no clinical benefit

FDA approves the initiation of stem cell study for protection against COVID-19

CellCentric enters agreement with PCCTC for phase II dose-expansion study of CCS-1477

Catalyst announces pivotal phase III design for MarzAA

Researchers in Montreal and NYU partner on new COVID-19 clinical study

IXT-v100 vaccine decreases meth-taking and -seeking behaviors in vivo

Preclinical data support development of WZ-66 for NASH

Roche patents Toll-like receptor antagonists

Beijing Yuezhikangtai Biomedicines discloses VEGFR inhibitors

Forge Therapeutics presents new bacterial LpxC inhibitors

Investigator-initiated IND application filed to study CORVax12 to prevent COVID-19

New USP9X inhibitors identified by FORMA Therapeutics

Biogen describes new OGA inhibitors

New nitrofuran-class antibiotic IITR-06144 shows efficacy against resistant bacteria

FDA clears Polaryx's IND for PLX-200 in juvenile neuronal ceroid lipofuscinosis

Emapalumab and anakinra studied to reduce hyperinflammation and respiratory distress in COVID-19

Kolon begins first-in-human study of KLS-2031 for neuropathic pain from lumbosacral radiculopathy

Selective circadian regulation may yield new therapies

New HDAC6 inhibitors show promise in Charcot-Marie-Tooth disease cell model

GPR56 found to be tied with antidepressant treatment response

Viriom opens phase II study of NNRTI elsulfavirine for COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...